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RESEARCH ARTICLE
Overview of Benign and Malignant Prostatic Disease in
Pakistani Patients: A Clinical and Histopathological Perspective
Huma Arshad, Zubair Ahmad*
Abstract
Background: To present the overall clinical and histological perspective of benign and malignant prostatic
disease as seen in our practice in the Section of Histopathology, Department of Pathology and Microbiology,
Aga Khan University Hospital, Karachi, Pakistan. Materials and Methods: All consecutive prostate specimens
(transurethral resection or TUR, enucleation, needle biopsies) received between July 1, 2012 and December 31,
2012 were included in the study. Results: Of the total of 785 cases, 621 (79.1%) were TUR specimens, 80 (10.2%)
enucleation specimens, and 84 (10.7%) needle biopsies. Some 595 (75.8%) were benign, while 190 (24.2%) were
malignant. Mean weight of BPH specimens was 19 grams and 43 grams for TUR and enucleation specimens
respectively. Almost 67% of adenocarcinomas were detected on TUR or enucleation specimens. Of the above
cases, 41.7% were clinically benign while 58.3% were clinically malignant. The average volume of carcinoma in
all cases ranged between 60 to 65%. The average number of cores involved in needle biopsies was 5. In general,
higher Gleason scores were seen in TUR/enucleation specimens than in needle biopsies. Overall, in all types of
specimens, commonest Gleason score was 7, seen in 74 (38.9%) cases, followed by Gleason score 9 seen in 47
(24.7%) cases. Out of the 63 needle biopsies with carcinoma, radical prostatectomy was performed in 16 cases
(25.4%). Conclusions: Benign prostatic hyperplasia (BPH) is extremely common and constitutes the bulk of
prostate specimens. TMajority of prostatic carcinomas are still diagnosed on TUR or enucleation specimens.
These included both clinically benign and clinically malignant cases. The volume of carcinoma in these specimens
was quite high indicating extensive disease. Gleason scores were also generally high compared with scores from
needle biopsies. Commonest Gleason score in all type of specimens was 7. Pathologic staging was possible in
very few cases since radical prostatectomies are rarely performed.
Keywords: Benign prostatic hyperplasia - prostatic carcinoma - TUR - enucleation - needle biopsy - Pakistan
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Introduction
Pakistan is a large South Asian country with
a population of over 180 million. The Section of
Histopathology at the Aga Khan University Hospital
in Karachi (Pakistan’s largest city) is the biggest and
premier center for Histopathology in Pakistan. We receive
specimens from the entire country through our collection
points located throughout Pakistan. We annually report
over 50,000 cases of surgical pathology.
We commonly see cases of benign prostatic hyperplasia
(BPH) and prostatic adenocarcinoma in our practice, and
our studies have shown that prostatic carcinoma is among
the commonest malignancies in older males (Zubair et
al., 2007a; 2007b). In the West, owing to the availability
of other treatment options e.g. pharmacologic for BPH,
the frequency of transurethral resection (TUR) or open
transvesical prostatectomy (enucleation) specimens has
greatly reduced (Epstein and Netto, 2010). However,

this is not the case in Pakistan where the treatment of
BPH remains overwhelmingly surgical. In fact, TUR and
enucleation are performed for diagnostic and therapeutic
purposes even in those cases where there is clinical
suspicion of carcinoma. These cases include nonpalpable
tumors with raised serum prostate specific antigen (PSA)
levels (clinical stage T1c), and palpable tumors (clinical
stage T2 or T3). Serum PSA testing is becoming more
common in Pakistan, and the number of prostatic needle
biopsies (and T1c cancers detected on these) is also
increasing albeit gradually. However, the majority of
prostatic adenocarcinomas in Pakistan are still diagnosed
on TUR or open transvesical prostatectomy specimens.
We had earlier published two studies on radical
prostatectomy specimens and needle biopsies (Memon
et al., 2009; Ahmad et al., 2012) The aim of the current
study is to present the overall clinical and histological
perspective of benign and malignant prostatic disease as
seen in our practice.
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All consecutive prostatic specimens (TUR,
enucleation and needle biopsies) received in the Section
of Histopathology, Department of Pathology and
Microbiology, Aga Khan University Hospital, Karachi
over a six month period (July 1 to December 31, 2012)
were included in the study. Cases of both BPH and
adenocarcinoma were included. All specimens were
processed and reported according to standard protocols.
All relevant data was recorded and analyzed using
commercially available SPSS 19.0 software package.
Fisher exact and chi square tests were used to calculate
p-values for different variables. P-value equal to or less
than 0.05 was considered significant.

Results
A total of 785 prostate specimens were received
during the study period. These included 621 (79.1%)
TUR specimens, 80 (10.2%) enucleation specimens,
and 84 (10.7%) needle biopsies. Out of 785 cases, 595
(75.8%) were benign, while 190 (24.2%) were malignant
(carcinoma). The breakup of all 785 cases is shown in
Table 1. BPH was most commonly seen in the seventh
decade. The decade wise breakup of BPH is shown in
Table 2. Age range of BPH was 41 to 92 years. The weight
of BPH specimens treated by TUR ranged from 2 to 72
grams with mean weight of 19 grams. On the other hand,
the weight of BPH specimens treated by enucleation
ranged from 6 to 150 grams with mean weight of 43 grams.
Out of the 574 cases of BPH detected on TUR or
enucleation specimens (Table 1), 28 (4.9%) had serum
PSA in the borderline range (4-10) and a suspicion of
malignancy was raised by the clinician. The average
number of sections submitted in both benign (BPH) and
Table 1. Breakup of Prostate Specimens According to
Type of Specimen (n=785)
1
2
3

TUR
Enucleation
Needle Biopsy

Total No.

BPH

Carcinoma

621
80
84

527 (84.9%)
47 (58.8%)
21 (25%)

94 (15.1%)
33 (41.2%)
63 (75%)

1
2
3
4
5

41-50
51-60
61-70
71-80
>80

Number of cases
31
140
239
145
40

Percentage (%)
5.20%
23.50%
40.20%
24.40%
6.70%

Type of Specimen Total No. Clinically Benign Clinically Malignant

1
2

TUR
Enucleation

94
33

31 (33%)
22 (66.7%)

63 (67%)
11 (33.3%)

Table 5. Breakup of Gleason Score in Our Cases
(n=190)
Gleason score

Number of cases

Percentage (%)

--2
29
74
37
47
1

--1.00%
15.30%
38.90%
19.50%
24.70%
0.50%

4
5
6
7
8
9
10

100.0
6.3

Table 6. Breakup of Gleason Score in Carcinoma75.0
Detected on TUR and Enucleation Specimens (n=127)
Gleason score Clinically Benign

4
5
6
7
8
9
10

Table 2. Decade Wise Breakup of Cases of BPH (n=595)
Age (years)

Table 4. Breakup of Carcinomas Detected on TUR
and Enucleation Specimens According to Clinical
Impression (n=127)

----11 (20.7%)
19 (35.8%)
10 (18.9%)
12 (22.7%)
1 (1.9%)

Clinically Malignant

--2 (2.7%)
4 (5.4%)
23 (31.1%)
16 (21.6%)
29 (39.2%)
---

Overall

50.0
-2 (1.6%)
15 (11.8%)
42 (33.1%)
26 (20.5%) 25.0
41 (32.2%)
1 (0.8%)

100.0
Table 7. Breakup of Gleason Score in Patients 65 Years 0
100.0
and Older (n=130)
100.0
6.3

Gleason Score

75.0

10.1

20.3
Number of
cases

6
7
8
9 56.3
10

20
49
22
38
154.2

Percentage (%)
25.015.40%

Types of specimens

3+4 4+3 Total

25.0Needle Biopsy

75.0

11

50.0
50.0
30.0
%

25.0

32 43.20%
25.0
25.70%
30.0
23 31.10%

7 19
31.3
14

0
Remission
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21
38.0
Clinically31.3
benign TUR/enucleation
12
23.7 9
Clinically malignant TUR/enucleation
r recurrence

3.70%
20.00%
38.90%
26.30%
11.10%

treatment

3006

7
38
74
50
21

t treatment

41-50
51-60
61-70
71-80
>80

75.0
30.0

37.70%
16.90%
29.20%
0.80%

Table 3. Decade Wise Breakup of Cases of Carcinoma
46.8
(n=190)
Age (years)
Number of cases
Percentage (%)50.0
31.3
Table 8. Breakup of Gleason Score 7 (n=74)
1
2
3
4
5

56.3

0

0

None

Type of Specimen

malignant TUR and enucleation specimens was 3 to 4.
However, in cases with borderline serum PSA or clinical
suspicion of malignancy, the specimens were submitted
entirely. Similarly, the 21 cases which turned out to be
benign on needle biopsy (Table 1) had serum PSA in the
borderline range.
Carcinoma was most commonly seen in the seventh
decade. The decade wise breakup of cases of carcinoma
is shown in Table 3. Age range for adenocarcinoma was
45 to 86 years. Mean and median age was 56 and 59 years
respectively. Overall 130 out of 190 patients (68.4%)
were 65 years in age or older. As seen in table 1, 127
(66.8%) out of total 190 cases of adenocarcinoma were
detected on TUR and enucleation specimens, 53 (41.7%)
were clinically benign (clinical stage T1a or T1b), while
74 (58.3%) were clinically malignant. The breakup is
shown in Table 4. Out of 53 cases which were clinically

31.3

6.3
Newly diagnosed without treatment

Materials and Methods

12.8
6.3

56.3

51.1
56.3

31.3
33.1
31.3
hout treatment
treatment
emotherapy
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benign, 2 (3.8%) were clinical stage T1a, while 51 (96.2%)
were clinical stage T1b. Out of the 74 cases which were
clinically malignant, 10 (13.5%) were T1c, while 64
(86.5%) were T2 or T3.
The average volume of carcinoma in clinically
benign TUR/enucleation specimens was 60%, while
average volume of carcinoma in clinically malignant
TUR/enucleation specimens was 65%. Of the 63 needle
biopsies with carcinoma, 53 (84.1%) were sextant and 10
(15.9%) were octant. The average volume of carcinoma
in needle biopsies was 60% and the average number of
cores involved was 5.
The breakup of Gleason score in all 190 cases is shown
in Table 5. The breakup of Gleason score in clinically
benign and clinically malignant TUR/ enucleation
specimens is given in Table 6. As shown in Table 6,
Gleason score was 8 or above in 43% of clinically
benign and 61% of clinically malignant TUR/enucleation
specimens. The p-value was significant (0.013). In needle
biopsies, Gleason score was 6 in 14 cases (22.2%), 7 in
32 cases (50.8%), 8 in 11 cases (17.5%) and 9 in 6 cases
(9.5%). Out of the 63 needle biopsies with carcinomas,
radical prostatectomy was performed in 16 cases (25.4%).
As mentioned above, 130 (68.4%) of patients with
carcinoma were 65 years or older. The average volume
of carcinoma in specimens from these patients was 63%.
The breakup of Gleason score in these 130 patients is
shown in Table 7. Out of 190 patients, 60 (31.6%) were
under 65 years of age. The average volume of carcinoma
in these patients was 57%. In these 60 patients, Gleason
score was 6 in 7 cases (11.7%), 7 in 20 cases (33.3%),
8 in 13 cases (21.7%), 9 in 18 cases (30%) and 10 in 2
cases (3.3%). So Gleason score was 7 and above in almost
85% patients who were 65 years or older and in over 88%
patients under 65 years of age. The difference was not
statistically significant (p-value 0.578).
A total of 74 cases of carcinoma out of 190 had Gleason
score 7. Of these, 42 had Gleason grade 3+4=7, and 32
had Gleason grade 4+3=7. The breakup is shown in Table
8. So, Gleason score 7 was overall the commonest score
in our series followed by Gleason score 9.
As shown in Table 6 and in our results above, almost
86% of all TUR/enucleation specimens showed a Gleason
score 7 or above, while almost 73% of needle biopsies had
a Gleason score 6 or 7. The difference was statistically
significant (p-value: 0.000).

Discussion
Benign prostatic hyperplasia is extremely common
and constitutes the bulk of prostatic specimens. As seen
in our results, most cases of BPH are treated by TUR
rather than suprapubic prostatectomy, although studies
have shown that chances of a patient undergoing another
surgery for BPH is much higher after TUR than suprapubic
prostatectomy (Roos et al., 1989). The mean weight of
BPH specimens in our series was 19 grams for TUR
and 43 grams for enucleation specimens. According to
literature, the average weight of BPH specimens obtained
by TUR and enucleation is around 33 (±16) and 100 grams
respectively (Rosai, 2011).

Clinical staging of prostatic adenocarcinoma is based
on the TNM system (Epstein et al., 2007).
Clinical stage T1a and T1b carcinomas are tumors
that are not suspected clinically and are discovered in
TUR or enucleation specimens removed for BPH. T1a is
carcinoma involving less than 5% of the specimen, while
T1b is carcinoma involving more than 5% of the specimen
(Epstein and Netto, 2010). Clinical stage T1a carcinomas
may only be monitored with serum PSA levels, however
sometimes radical prostatectomy is performed (Larsen et
al., 1991). T1b carcinomas are usually treated by radical
prostatectomy or radiotherapy (Christensen et al., 1990).
Clinical stage T1c carcinomas are non-palpable tumors
which are diagnosed by needle biopsy in patients with
raised serum PSA levels. T1c carcinomas are usually
treated by radical prostatectomy. Clinical stage T2
carcinomas are palpable tumors which are still confined
to the prostate. T2 carcinomas are also usually treated by
radical prostatectomy. Clinical stage T3 carcinomas are
tumors which have extended beyond the prostate and are
usually treated by radiotherapy (Epstein and Netto, 2010).
The majority of prostatic carcinomas in our practice are
still diagnosed on TUR or enucleation specimens. Owing
to the availability of non-surgical treatment options, the
number of TUR and enucleation specimens has declined
in the west (Epstin and Netto, 2010). However, this is
not the case in our country, and TUR and enucleation
specimens remain the most common prostatic specimens
received in the surgical pathology laboratory. As shown
in the results, the overwhelming majority of clinically
unsuspected carcinomas which were discovered in TUR
or enucleation specimens performed for BPH (i.e. clinical
stage T1a or T1b) were T1b (more than 5% of the specimen
involved by the tumor). The presence of carcinoma in
a TUR specimen may signify extensive spread from
the periphery of the gland. The probability of detecting
carcinoma in TUR specimens is directly related to the
amount of sampling (Newman et al., 1982). If five to eight
blocks are submitted, all clinical stage T1b carcinomas are
detected, and if eight to ten blocks are submitted, more
than 90% stage T1a carcinomas are detected (Murphy
et al., 1986; Vollmer 1986; Eble and Epstein, 1990).
Remaining tissue should be submitted if cancer is stage
T1a, but not if cancer is stage T1b (McDowell et al.,
1994). The average volume of carcinoma in our clinical
stage T1 cases was 60%. The fact that an average of three
to four blocks was originally submitted in these cases
indicates the presence of extensive and widespread cancer.
One plausible reason why we see so much carcinoma in
ostensibly benign cases is that no investigations e.g. serum
PSA, transrectal ultrasound (TRUS) were carried out in
many of these cases. It must be noted that carcinoma can
diffusely infiltrate the gland without causing a palpable
nodule. At other times, the carcinoma may be well defined
and peripherally located but may remain unpalpable for
reasons that are still not clear (Epstein and Netto, 2010).
However, the main reason in our scenario probably is
the failure to carry out any investigations due to lack of
availability of these tests, patient non-affordability etc.
Our results show that the majority (58.3%) of
carcinomas detected on TUR or enucleation specimens
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were clinically malignant (clinical stage T2 or T3).
However, even in such cases, TUR or enucleation rather
than radical prostatectomy was performed, simply because
the latter option is not available anywhere in Pakistan
except at our center in Karachi. This is the situation in
a country with a population of 180 million people. As
shown in table 4, as many as 67% of carcinomas detected
on TUR and over 33% detected on enucleation specimens
were clinically malignant. Following TUR or enucleation,
these patients then underwent radiotherapy. As shown in
the results, TUR or enucleation was also performed in 10
cases which were stage T1c.
The average volume of carcinoma in clinically
malignant TUR or enucleation specimens was 65% which
was not significantly higher than the average volume of
60% seen in clinically benign T1 specimens. Only 33% of
carcinomas in our series were detected on needle biopsies.
Our practice does not demonstrate the trend of most cases
being diagnosed on needle biopsies which is evident even
in some Asian countries (Kuo et al., 2012). The average
overall volume in our needle biopsies was 60%. It may be
mentioned here that those TUR and enucleation specimens
which were clinically suspicious for carcinoma but in
which no carcinoma or only limited carcinoma (involving
less than 5% of the submitted tissue) was found, were then
submitted entirely. The algothims for additional sampling
of TUR specimens were followed (McDowell et al., 1994).
Studies have shown that patients in whom carcinoma is
discovered in clinically benign TUR specimens have
higher rates of tumor dissemination than those diagnosed
by needle biopsy because tumors diagnosed incidentally
in TUR specimens are usually more advanced (Forman
et al., 1986).
The average volume of carcinoma in patients 65 years
or older was 63%, while in those under 65 years of age,
it was 57%.
It is important to note at this point that tumor volume
whether on needle biopsies or TUR is an important
prognostic marker that correlates well with Gleason score,
extraprostatic tumor extension, seminal vesicle invasion,
positive surgical margins and lymph node metastases on
radical prostatectomy specimens (Schmid and McNeal,
1992). In fact, one study has shown that a simple visual
estimate (eyeballing) of tumor volume is more closely
associated with survival than serum PSA level and
microscopic Gleason score (Vollmer, 2009). A recent study
which looked at the current trends in visually estimated
tumor volume found a rising incidence of very low volume
(0-1%) tumors in radical prostatectomy specimens (Green
et al., 2012). In needle biopsies, the number of positive
cores and percentage of tumor in each core are very
strong predictors of adverse prognostic features in radical
prostatectomy specimens (Sebo et al., 2000; Freedland et
al., 2002; 2003).
The Gleason microscopic grade of carcinoma is
an important prognostic marker (Zincke et al., 1994).
There is convincing evidence that microscopic Gleason
score is superior to other variables as an independent
prognostic marker (Lilleby et al., 2001). Various studies
have shown good correlation between Gleason score and
various important pathological features seen in radical
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prostatectomy specimens, and with outcome following
radical prostatectomy and radiotherapy (Epstein et al.,
1996; Green et al., 1998; Rubin et al., 2004; Kryvenko
et al., 2012). The International Society of Urological
Pathology Consensus Conference modified the Gleason
grading in 2005 (Shah et al., 2009) according to which
Gleason grades were updated according to new criteria.
Several studies have validated the prognostic value of
these modifications (Billis et al., 2008; Dong et al., 2012).
As shown in Table (5), Gleason score 7 was the commonest
score in our series, followed by Gleason score 9. As shown
in Table 6, higher Gleason scores (8 or 9) were more
frequent in clinically malignant than in clinically benign
carcinomas detected on TUR or enucleation specimens.
On the other hand, Gleason score 6 was much more
common in carcinomas which were clinically benign. As
shown in table 6, about 43% of clinically benign cases
and over 61% of clinically malignant cases had Gleason
score 8 and above. The p-value was significant (0.013).
Overall, in carcinomas detected on TUR or enucleation
specimens, majority of patients had Gleason scores 7, 8
or 9, and Gleason score 9 was, in fact, the most common
score. On needle biopsies (see results), Gleason score
7 was the most common (50.8%), followed by scores 6
(22.2%) and 8 (17.5%). In needle biopsies with different
cores showing different grades, we report the grades
of each core separately as per recommendations. The
highest tumor grade is selected as the grade of the entire
case to determine treatment, regardless of the percent
involvement (Epstein et al., 2010). As shown in table 6,
about 86% patients with carcinoma detected on TUR or
enucleation specimens had Gleason score 7, 8, 9 or 10,
while 73% patients with carcinoma detected on needle
biopsies had Gleason score 6 or 7 (see results). The p-value
was significant (0.000). As shown in table 7, over 84%
patients with carcinoma who were 65 years or older had
Gleason score 7 to 10. Similarly, as shown in results, over
88% patients who were under 65 years of age had Gleason
scores 7 to 10. The p-value was not significant (0.578%).
In our study, therefore, there was no significant correlation
of age with adverse prognosis. However, a recent study
from China (Wang et al., 2012) reported that prostatic
cancer patients under 59 years of age had more aggressive
disease. However, another recent study did not find any
statistically correlation between Gleason score and age of
the patients (Sapira and Obiorah, 2012).
Although clinical stage T1c carcinomas are usually
treated by radical prostatectomy (Epstein et al., 2010),
this is not the case in our country due to reasons already
discussed above. Radical prostatectomy was performed
in only 16 out of 63 cases (25.4%). This is only slightly
better than what we found in an earlier study (Memon et
al., 2009). The number of radical prostatectomies over the
years has increased but very slowly. Currently, the total
number performed per year is around thirty.
However, our findings on radical prostatectomy
specimens in the present study as well as previous studies
(Memon et al., 2009; Ahmad and Arshad, 2012) mostly
show advanced pathologic stage with majority of cases
showing extraprostatic extension, seminal vesicle invasion
and positive surgical margins. Because so few radical
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multivariate analysis of 721 men with long-term follow-up.
prostatectomies are performed, pathologic staging of
Am J Surg Pathol, 20, 286-92.
prostatic carcinoma in our setting is only possible in a
Freedland SJ, Aronson WJ, Terris MK, et al (2003). Percent
very limited number of cases.
of prostate needle biopsy cores with cancer is a significant
Recently, studies have shown the effectiveness and
independent predictor of prostate specific antigen recurrence
safety of brachytherapy and combined vascular endothelial
following radical prostatectomy: results from SEARCH
growth factor receptor/platelet derived growth factor
database. J Urol, 169, 2136-41.
receptor (VEGFR/PDGFR) inhibitor. Therapy in the
Freedland SJ, Csathy GS, Dorey F, Aronson WJ (2002). Percent
treatment of localized but high risk prostate cancer (Corn
prostate needle biopsy tissue with cancer is more predictive
et al., 2013).
of biochemical failure or adverse pathology after radical
prostatectomy than prostate specific antigen or Gleason
The diagnosis and treatment of prostatic
score. J Urol, 167, 516-20.
adenocarcinoma is in the majority of cases suboptimal at
Forman JD, Order SE, Zinreich ES, et al (1986). The correlation
best. Most patients are managed with some form of surgery
of pretreatment transurethral resection of prostatic cancer
(TUR or suprapubic prostatectomy) plus radiotherapy
with tumor dissemination and disease-free survival. A
and/or antiandrogen therapy. As prostatic carcinoma in
univariate and multivariate analysis. Cancer, 58, 1770-8.
general is fortunately a relatively less aggressive type
Green IF, Bleach AD, Anchala PR, et al (2012). Trends in
of cancer, many patients respond to some extent to the
prostatic adenocarcinoma tumor volume by visual estimation
above mentioned forms of treatment and since the disease
in prostatectomy specimens. Pathol Res Pract, 208, 578-83
affects mainly the elderly, may infact ultimately die from
Green GA, Hanlon AL, Al-Saleem T, Hanks GE (1998) A
Gleason score of 7 predicts a worse outcome for prostate
some other cause.
carcinoma patients treated with radiotherapy. Cancer, 83,
971-6.
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